--- title: "Insmed To Present at March 2026 Investor Conferences | INSM Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/275898096.md" description: "Insmed Incorporated (Nasdaq: INSM) announced its participation in two upcoming investor conferences: the 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026, and the Leerink Partners Global Healthcare Conference in Miami on March 10, 2026. Both events will be webcast live and archived for 30 days. Insmed focuses on developing therapies for serious diseases, particularly in pulmonary and inflammatory conditions, and has been recognized as a top employer in the biopharmaceutical industry." datetime: "2026-02-13T04:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275898096.md) - [en](https://longbridge.com/en/news/275898096.md) - [zh-HK](https://longbridge.com/zh-HK/news/275898096.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275898096.md) | [繁體中文](https://longbridge.com/zh-HK/news/275898096.md) # Insmed To Present at March 2026 Investor Conferences | INSM Stock News , /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: - 46th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 2, 2026, at 9:50 a.m. ET. - Leerink Partners Global Healthcare Conference in Miami, on Tuesday, March 10, 2026, at 8:00 a.m. ET. These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at **www.insmed.com**. Webcasts will be archived for a period of 30 days following the conclusion of the live events. **About Insmed** Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 _Science_ Top Employer. Visit **www.insmed.com** to learn more or follow us on **LinkedIn**, **Instagram**, **YouTube**, and **X**. **Contact:** Investors: Bryan Dunn Vice President, Investor Relations (646) 812-4030 investor.relations@insmed.com Media: Claire Mulhearn Vice President, Corporate Communications (862) 842-6819 media@insmed.com SOURCE Insmed Incorporated ### Related Stocks - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [Invesco Dorsey Wright Healthcare MomtETF (PTH.US)](https://longbridge.com/en/quote/PTH.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Insmed Incorporated (INSM.US)](https://longbridge.com/en/quote/INSM.US.md) ## Related News & Research - [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/en/news/278880252.md) - [Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer](https://longbridge.com/en/news/279596043.md) - [Mirum Pharmaceuticals Executives Sell Shares](https://longbridge.com/en/news/279503772.md) - [Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results](https://longbridge.com/en/news/279269040.md) - [NRx Pharma Says FDA Identifies No Bioequivalence Issues In Preservative-free Ketamine Application](https://longbridge.com/en/news/279426124.md)